The company's proprietary platform develops first-in-class therapeutics with customized and highly homogenous human glycans assembled onto glycoproteins in a site-specific manner, allowing healthcare companies to understand the role of glycans in human health and diseases. GlycoEra's bifunctional biologics (G-LyTACs) bind to disease-causing proteins and transport them to the lysosome using naturally occurring endocytic receptors, resulting in the degradation and removal of the proteins from the body. This technology can access targets that are extracellular and membrane proteins, opening up novel targets and therapeutic areas for intervention, positioning GlycoEra as the leading precision protein degradation company.